Therapy Areas: Diabetes
Oramed Pharmaceuticals reveals results from proof-of-concept study for oral leptin
24 December 2020 -

It was reported on Wednesday that Oramed Pharmaceuticals Inc (Nasdaq: ORMP) (TASE: ORMP), a Jerusalem-based clinical-stage pharmaceutical company, has revealed results from a proof-of-concept study for its oral leptin drug candidate.

The product was approved by Israel's Ministry of Health. The single dose study assessed oral leptin's safety and pharmacodynamics (glucagon and glucose reduction) in type 1 diabetic patients.

The study enrolled ten patients, with seven randomised to receive one capsule of leptin and three randomised to receive a placebo. The study revealed that patients who received leptin on average had a reduction in glucose as compared to the placebo group during the first 30-180 minutes following dosing.



Related Headlines